Howard Shore

Portrait photograph of Howard Shore Tate Trustee

Howard Shore

Howard Shore is an international entrepreneur and philanthropist, whose business interests originated in stockbroking and now span various alternative asset classes including real estate, MedTech and growth capital. His philanthropic interests cover healthcare, education and the arts, including sponsoring the Shore Initiative for Melanoma Diagnostic Imaging at the Memorial Sloan Kettering Cancer Centre, which aims to utilise artificial intelligence to reduce Melanoma mortality through early detection. He was appointed to the Board of the Prostate Cancer Foundation (PCF) in 2023.

Howard began his career in discretionary fund management with Grieveson Grant and Co., and subsequently became one of the first financial futures brokers when the LIFFE market was established in 1982. Between 2001 and 2003, he served as a non-executive director at Tottenham Hotspur PLC.

Howard founded Shore Capital Group in 1985 and built it up to be one of the UK’s leading independent investment groups specialising in principal finance, capital market activities and asset management. He remains chairman and majority shareholder but relinquished operational responsibilities in 2017.

Appointment information

  • Appointed by: Prime Minister
  • Appointment: 7 January 2022
  • Term expires: 6 January 2026

Other membership

  • Executive Trustee, Tate Foundation